<DOC>
	<DOC>NCT00552058</DOC>
	<brief_summary>The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.</brief_summary>
	<brief_title>Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>male/female 18 75 years inclusive diagnosis of Crohn's disease confirmed moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 450) no previous treatment with antitumor necrosis factor (antiTNF) medications previous participation in a certolizumab pegol study general exclusion criteria as common for studies in this indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>CDP 870</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CIMZIA Â®</keyword>
	<keyword>Crohn's disease</keyword>
	<keyword>Induction</keyword>
	<keyword>Clinical remission</keyword>
	<keyword>Clinical response</keyword>
</DOC>